[go: up one dir, main page]

BRPI0518829A2 - mÉtodo para o tratamento de dor neuropÁtica e sÍndromes associadas - Google Patents

mÉtodo para o tratamento de dor neuropÁtica e sÍndromes associadas

Info

Publication number
BRPI0518829A2
BRPI0518829A2 BRPI0518829-6A BRPI0518829A BRPI0518829A2 BR PI0518829 A2 BRPI0518829 A2 BR PI0518829A2 BR PI0518829 A BRPI0518829 A BR PI0518829A BR PI0518829 A2 BRPI0518829 A2 BR PI0518829A2
Authority
BR
Brazil
Prior art keywords
treatment
neuropathic pain
associated syndromes
syndromes
ibudilast
Prior art date
Application number
BRPI0518829-6A
Other languages
English (en)
Inventor
Kirk W Johnson
Lance Sultzbaugh
Jennifer Shumilla
Original Assignee
Avigen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avigen Inc filed Critical Avigen Inc
Publication of BRPI0518829A2 publication Critical patent/BRPI0518829A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • AIDS & HIV (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

MÉTODO PARA O TRATAMENTO DE DOR NEUROPÁTICA E SINDROMES ASSOCIADAS. A presente invenção é dirigida ao uso de ibudilast para o tratamento de dor neuropática.
BRPI0518829-6A 2004-12-06 2005-12-06 mÉtodo para o tratamento de dor neuropÁtica e sÍndromes associadas BRPI0518829A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US63424804P 2004-12-06 2004-12-06
US66527605P 2005-03-25 2005-03-25
US71633305P 2005-09-12 2005-09-12
PCT/US2005/044258 WO2006063048A2 (en) 2004-12-06 2005-12-06 Ibudilast for treating neuropathic pain and associated syndromes

Publications (1)

Publication Number Publication Date
BRPI0518829A2 true BRPI0518829A2 (pt) 2008-12-09

Family

ID=36476178

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0518829-6A BRPI0518829A2 (pt) 2004-12-06 2005-12-06 mÉtodo para o tratamento de dor neuropÁtica e sÍndromes associadas

Country Status (8)

Country Link
US (2) US7534806B2 (pt)
EP (1) EP1835913A2 (pt)
JP (2) JP4954085B2 (pt)
AU (1) AU2005314133B2 (pt)
BR (1) BRPI0518829A2 (pt)
CA (1) CA2587791C (pt)
MX (1) MX2007006777A (pt)
WO (1) WO2006063048A2 (pt)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5411504B2 (ja) * 2005-09-26 2014-02-12 メディシノバ， インコーポレイテッド 薬物嗜癖および行動嗜癖を治療するためのイブジラストの使用
US20070191365A1 (en) * 2006-01-13 2007-08-16 Lance Sultzbaugh 3,4,6-Substituted pyridazines for treating neuropathic pain and associated syndromes
US20070281924A1 (en) * 2006-05-31 2007-12-06 Gaeta Federico C MIF inhibitors for treating neuropathic pain and associated syndromes
US7622256B2 (en) * 2006-05-31 2009-11-24 Avigen, Inc. Method for selecting compounds that modulate MIF-induced expression of ICAM-1 and/or VCAM-1
JP5352452B2 (ja) * 2006-06-06 2013-11-27 メディシノバ， インコーポレイテッド 置換ピラゾロ［１，５−ａ］ピリジン化合物およびその使用方法
WO2008057496A2 (en) * 2006-11-09 2008-05-15 Avigen, Inc. Method for treating delirium
EP2131841B1 (en) * 2007-01-30 2012-08-01 Avigen, Inc. Methods for treating acute pain
WO2008137012A1 (en) * 2007-05-03 2008-11-13 Avigen, Inc. Use of a glial attenuator to prevent amplified pain responses caused by glial priming
BRPI0814624A2 (pt) 2007-07-11 2015-01-27 Medicinova Inc Tratamento de doença neurodegenerativa progresiva com ibudilaste
US20090028816A1 (en) * 2007-07-27 2009-01-29 Lance Sultzbaugh Treatment of depression, psychosis, and anxiety
CN103068394A (zh) * 2010-04-15 2013-04-24 皇家学习促进学会/麦吉尔大学 对于疼痛的局部治疗
RU2459642C2 (ru) * 2010-04-27 2012-08-27 Министерство обороны Российской Федерации, Государственное образовательное учреждение высшего профессионального образования Военно-медицинская академия им. С.М. Кирова (ВМедА) Способ лечения травматических невропатий
SI2600851T1 (en) 2010-08-04 2018-07-31 Gruenenthal Gmbh PHARMACEUTICAL FORM OF DOSAGE COVERING 6'-FLUORO- (N-METHYLLINE N, N-DIMETHYL-4-PHENYL-4 ', 9'-DIHYDRO-3'H-SPIRO- (CYCLOHEXANE-1,1'- PIRANO (3,4, B) INDOL) -4-AMIN, FOR NON-PROPHETIC DISEASE TREATMENT
CN111789956B (zh) * 2011-04-27 2023-02-17 耶鲁大学 用于抑制化疗引起副作用的药物治疗、筛选技术和试剂盒
JP2017537881A (ja) * 2014-11-18 2017-12-21 ピクサーバイオ コーポレーション 急性、術後、または慢性疼痛を治療する組成物およびその使用方法
CA2967826C (en) 2014-11-26 2024-01-16 Medicinova, Inc. A combination of ibudilast and riluzole and methods of using same
WO2017160599A1 (en) 2016-03-14 2017-09-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of cd300b antagonists to treat sepsis and septic shock
EP3488220A4 (en) * 2016-11-29 2020-03-04 Axim Biotechnologies, Inc. CHEWING GUM COMPOSITION WITH CANNABINOIDS AND GABAPENTIN
US10391085B2 (en) 2016-12-22 2019-08-27 Medicinova, Inc. Methods of treating glioblastoma multiforme using ibudilast
US10744123B2 (en) 2018-02-12 2020-08-18 Medicinova, Inc. Methods and dosing regimens using ibudilast and a second agent for cancer therapy
EP3740205B1 (en) * 2018-02-12 2023-09-20 MediciNova, Inc. Methods of suppressing myeloid-derived suppressor cells in patients
JP2022504435A (ja) 2018-10-09 2022-01-13 メディシノバ・インコーポレイテッド イブジラストとインターフェロン－ベータとの組み合わせ、およびそれを使用する方法
ES2970996T3 (es) 2018-10-19 2024-06-03 Medicinova Inc Tratamiento de la lesión macular asociada a la esclerosis múltiple con ibudilast
WO2020251748A1 (en) * 2019-06-11 2020-12-17 Yale University Novel treatment for wolfram syndrome
US11865214B2 (en) 2019-09-23 2024-01-09 Medicinova, Inc. Ibudilast oral formulations and methods of using same
EP4132521A1 (en) 2020-04-06 2023-02-15 MediciNova, Inc. Methods of reducing plasma level of macrophage migratory inhibitory factor in patients with ibudilast
JP2024506840A (ja) * 2021-01-29 2024-02-15 メディシノバ・インコーポレイテッド 化学ガス曝露を処置する方法
CA3226898A1 (en) 2021-07-26 2023-02-02 Kazuko Matsuda Ibudilast for preventing eye cancer metastasis
JP2024535880A (ja) 2021-09-21 2024-10-02 メディシノバ・インコーポレイテッド 膠芽腫の治療における使用のための併用療法におけるイブジラスト
US12042485B2 (en) 2021-10-07 2024-07-23 Medicinova, Inc. Methods of minimizing cancer metastasis
CN118973574A (zh) 2022-02-01 2024-11-15 美迪诺亚公司 异丁司特治疗新冠肺炎后遗症的用途
US20240016729A1 (en) * 2022-07-13 2024-01-18 Medicinova, Inc. Injectable formulations of ibudilast

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6263520A (ja) * 1985-09-14 1987-03-20 Kyorin Pharmaceut Co Ltd 抗リウマチ剤
AU6111796A (en) * 1995-06-12 1997-01-09 G.D. Searle & Co. Compositions comprising a cyclooxygenase-2 inhibitor and a 5 -lipoxygenase inhibitor
US20040014761A1 (en) 1997-10-28 2004-01-22 Place Virgil A. Treatment of female sexual dysfunction with phosphodiesterase inhibitors
AU4543899A (en) 1998-06-08 1999-12-30 Advanced Medicine, Inc. Multibinding inhibitors of microsomal triglyceride transferase protein
US6395747B1 (en) * 1998-08-10 2002-05-28 Sauro Sakoda Remedies for multiple sclerosis
US20020068740A1 (en) 1999-12-07 2002-06-06 Mylari Banavara L. Combination of aldose reductase inhibitors and antihypertensive agents for the treatment of diabetic complications
US7135495B2 (en) 2000-03-09 2006-11-14 Ono Pharmaceutical Co., Ltd. Indole derivatives
AU2001244618A1 (en) * 2000-03-30 2001-10-15 Takeda Chemical Industries Ltd. Substituted 1,3-thiazole compounds, their production and use
WO2001074860A2 (en) 2000-03-31 2001-10-11 Curagen Corporation Methods of identifying integrin ligands using differential gene expression
GB0008269D0 (en) 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
DK1318140T3 (da) 2000-09-14 2011-07-18 Mitsubishi Tanabe Pharma Corp Nye amidderivater og medicinsk anvendelse deraf
US20020137755A1 (en) 2000-12-04 2002-09-26 Bilodeau Mark T. Tyrosine kinase inhibitors
EP1348443A4 (en) 2000-12-08 2005-07-06 Takeda Pharmaceutical COMBINED MEDICINES
CA2436739A1 (en) 2000-12-26 2002-07-04 Takeda Chemical Industries, Ltd. Combination agent
US20040097555A1 (en) 2000-12-26 2004-05-20 Shinegori Ohkawa Concomitant drugs
CA2437248A1 (en) 2001-02-02 2002-08-15 Takeda Chemical Industries, Ltd. Jnk inhibitor
WO2002098429A1 (en) 2001-06-07 2002-12-12 Pfizer Products Inc. Ethanolamine, diethanolamine or triethanolamine salt of zopolrestat
EP1402900A1 (en) 2001-06-11 2004-03-31 Takeda Chemical Industries, Ltd. Medicinal compositions
WO2003011289A1 (en) * 2001-07-31 2003-02-13 Pharmacia + Upjohn Company Treatment of chronic pain with 3-heterocyclyl- and 3-cycloalkyl-3-aryloxypropanamines
EP1420783A4 (en) 2001-08-03 2009-09-30 Takeda Pharmaceutical STABLE EMULSION COMPOSITION
CA2456754A1 (en) 2001-08-08 2003-02-20 Yuji Iizawa Benzazepine derivative, process for producing the same, and use
CA2457482A1 (en) 2001-08-09 2003-02-27 Kissei Pharmaceutical Co., Ltd. 5-amidino-n-(2-aminophenethyl)-2-hydroxybenzenesulfonamide derivative, medicinal composition containing the same, and intermediate therefor
CA2459515A1 (en) 2001-09-07 2003-03-20 Kazuhiko Torisu Indole derivatives
US7153852B2 (en) 2001-09-07 2006-12-26 Ono Pharmaceutical Co., Ltd. Indole compounds, process for producing the same and drugs containing the same as the active ingredient
US20050014787A1 (en) 2001-11-09 2005-01-20 Masahiko Uchida 5-amidino-2-hydroxybenzenesulfonamide derivatives medicinal compoistions containing the same medicinal use thereof and intermediates in the production thereof
EP1336602A1 (en) 2002-02-13 2003-08-20 Giovanni Scaramuzzino Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases
CA2477715A1 (en) 2002-03-05 2003-09-12 Ono Pharmaceutical Co., Ltd. 8-azaprostaglandin derivative compound and agent comprising the compound as active ingredient
WO2003090748A1 (fr) 2002-04-24 2003-11-06 Takeda Pharmaceutical Compay Limited. Utilisation de composes a antagonisme anti-ccr
DE60318198T2 (de) 2002-05-02 2008-12-04 Merck & Co., Inc. Tyrosinkinase-hemmer
US20040053842A1 (en) 2002-07-02 2004-03-18 Pfizer Inc. Methods of treatment with CETP inhibitors and antihypertensive agents
JP2006507302A (ja) 2002-10-30 2006-03-02 メルク　エンド　カムパニー　インコーポレーテッド キナーゼ阻害剤
AU2003293529A1 (en) 2002-12-16 2004-07-29 Nitromed, Inc. Nitrosated and nitrosylated rapamycin compounds, compositions and methods of use
US20060083714A1 (en) 2003-01-27 2006-04-20 Warner James M Combination of a pde iv inhibitor and a tnf-alpha antagonist
CA2518506A1 (en) 2003-03-13 2004-11-18 Nitromed, Inc. Nitrosated and nitrosylated compounds, compositions and methods of use
CL2004000545A1 (es) 2003-03-18 2005-01-28 Pharmacia Corp Sa Organizada B Uso de un antagonista de los receptores de aldosterona y un antagonista de receptores de endotelina para el tratamiento o profilaxis de una condicion patologica relacionada con hipertension, disfuncion renal, insulinopatia y enfermedades cardiovascul
CL2004000544A1 (es) 2003-03-18 2005-01-28 Pharmacia Corp Sa Organizada B Uso de una combinacion farmaceutica, de un antagonista del receptor de aldosterona y un inhibidor de endopeptidasa neutral, util para el tratamiento y prevencion de una condicion patologica relacionada con hipertension, disfuncion renal, insulinopati
US20040266743A1 (en) 2003-05-09 2004-12-30 Pharmacia Corporation Combination of an aldosterone receptor antagonist and a renin inhibitor
TW200522932A (en) 2003-09-15 2005-07-16 Combinatorx Inc Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
TW200517114A (en) 2003-10-15 2005-06-01 Combinatorx Inc Methods and reagents for the treatment of immunoinflammatory disorders
NZ547389A (en) 2003-11-21 2009-11-27 Combinatorx Inc Combinations of a compound such as ibudilast and a corticosteroid for the treatment of inflammatory disorders

Also Published As

Publication number Publication date
MX2007006777A (es) 2007-08-06
US20060160843A1 (en) 2006-07-20
JP2008013577A (ja) 2008-01-24
AU2005314133A1 (en) 2006-06-15
CA2587791A1 (en) 2006-06-15
JP2008522979A (ja) 2008-07-03
WO2006063048A3 (en) 2006-08-24
AU2005314133B2 (en) 2012-03-08
CA2587791C (en) 2012-03-13
US7534806B2 (en) 2009-05-19
US20090209575A1 (en) 2009-08-20
WO2006063048A2 (en) 2006-06-15
EP1835913A2 (en) 2007-09-26
JP4954085B2 (ja) 2012-06-13

Similar Documents

Publication Publication Date Title
BRPI0518829A2 (pt) mÉtodo para o tratamento de dor neuropÁtica e sÍndromes associadas
BRPI0818366A2 (pt) Composto, pró-droga, medicamento, método inibidor de faah, métodos de profilaxia ou tratamento para ansiedade, ou depressão, ou de alívio da dor, e de profilaxia ou tratamento para dor inflamatória ou dor neuropática, e, uso do composto.
BRPI0908428A2 (pt) uso de ranozalina para tratar a dor.
BRPI0810354A2 (pt) Composto, uso de um composto, composição farmacêutica, e, método de tratamento de um dispositivo de dor
BRPI0512622A (pt) uso de compostos de peptìdeos para tratamento de tremor e outras sìndromes de tremor
EP1981526A4 (en) ADIPONECTIN FOR THE TREATMENT OF VARIOUS DISORDERS
BRPI0916862A2 (pt) compostos úteis para o tratamento de doenças degenerativas e inflamatórias
MX2008002293A (es) Uso novedoso de compuestos peptidicos para tratar dolor muscular.
DK1928438T3 (da) Anvendelse af ibudilast til behandling af stofafhængighed
BRPI0510043A (pt) método de tratamento de dor neuropática usando antagonista de receptor crth2
BRPI0820519A2 (pt) intermediário para a síntese do análogo de halicondrina b e reação de dessulfonilação usada para o intermediário
DE602005019899D1 (de) System zur behandlung von ischämischem schlaganfall
DE60322451D1 (de) 4-Tetrazolyl-4-Phenylpiperidinderivate zur Schmerzbehandlung
BRPI0816712A2 (pt) terapia de intervalo para o tratamento de tinnitus
CL2007002380A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento terapeutico y/o profilactico de la queratosis actinica.
BRPI0511995A (pt) uso de compostos peptìdicos para tratamento de dor em neuralgia trigeminal
LTC1912640I2 (lt) HDAC inhibitoriaus panobinostato panaudojimas mielomos gydymui
BRPI0509211A (pt) uso de compostos de peptìdeo para o tratamento de dor em neuropatia diabética
PT2054045E (pt) Utilização de derivados de 2,5-di-hidroxibenzeno para o tratamento da artrite e da dor
DK1863899T3 (da) Hudbehandlingspræparater
DK1838318T3 (da) Anvendelse af oxycodon til behandling af visceral smerte
MX2007014638A (es) Dispositivo perforador de la piel para el tratamiento del acne.
CL2011000100A1 (es) Uso de un inhibidor de desacetilasa de histona para el tratamiento de la enfermedad de hodgkin.
BRPI0923688A2 (pt) compostos e métodos para o tratamento de dor e outras doenças
BRPI0911515A2 (pt) dispositivos formadores rotatórios e métodos para o uso de tais dispositivos.

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2283 DE 07/10/2014.

B25B Requested transfer of rights rejected

Owner name: AVIGEN, INC (US)